At inflammatory sites, high levels of proinflammatory cytokines such as GM-CSF and TNF α can enhance the release of ROS, and anti-TNF α therapy is very beneficial in RA (97), As (98), Crohn’s disease (99) and other autoimmune diseases and infectious diseases. This evidence concerns the gene TNF and Crohn disease.